AE, n (%) | Daclizumab 150 mg SC |
---|---|
(N = 410) | |
MS relapse | 89 (22) |
Nasopharyngitis | 51 (12) |
Upper respiratory tract infection | 49 (12) |
Increased ALT | 37 (9) |
Pharyngitis | 35 (9) |
Headache | 33 (8) |
Urinary tract infection | 31 (8) |
Back pain | 29 (7) |
Increased AST | 28 (7) |
Rash | 27 (7) |
Diarrhea | 22 (5) |
Allergic dermatitis | 21 (5) |
Viral respiratory tract infection | 20 (5) |
Bronchitis | 19 (5) |
Oral herpes | 19 (5) |